Clinical review on triglycerides. (25th November 2019)

• Record Type: Journal Article
• Authors: Laufs, Ulrich; Parhofer, Klaus G; Ginsberg, Henry N; Hegele, Robert A
• Is Part Of: European heart journal. Volume 41:Number 1(2020)
• Page Start: 99
• Page End: 109c
• Publication Date: 2019-11-25
• Subjects: Triglycerides -- Review -- Lipoproteins -- Treatment -- Hypertriglyceridaemia; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.12005
• DOI: 10.1093/eurheartj/ehz785
• Languages: English
• ISSNs: 0195-668X

Abstract

Abstract: Hypertriglyceridaemia is a common clinical problem. Epidemiologic and genetic studies have established that triglyceride-rich lipoproteins (TRL) and their remnants as important contributors to ASCVD while severe hypertriglyceridaemia raises risk of pancreatitis. While low-density lipoprotein is the primary treatment target for lipid lowering therapy, secondary targets that reflect the contribution of TRL such as apoB and non-HDL-C are recommended in the current guidelines. Reduction of severely elevated triglycerides is important to avert or reduce the risk of pancreatitis. Here we discuss interventions for hypertriglyceridaemia, including diet and lifestyle, established treatments such as fibrates and omega-3 fatty acid preparations and emerging therapies, including various biological agents.